Racial and Ethnic Disparities in Established Cardiovascular Disease

How Large Are the Mortality Gaps, and Where Do They Come From?

Cardiovascular disease remains the leading cause of death in the United States across all major racial and ethnic groups, but the burden is not shared equally. Age-adjusted CVD mortality is highest in Black Americans, followed by white Americans, with Hispanic, Asian, and Pacific Islander populations recording lower aggregate rates. Those aggregate numbers, however, mask substantial within-group variation and obscure critical differences in the age at which disease strikes.

Black Americans: Earlier Onset, Higher Death Rates

Black adults develop hypertension roughly a decade earlier than white adults and sustain higher blood-pressure levels even after initiating treatment. The 2024 AHA Heart Disease and Stroke Statistics report puts hypertension prevalence at 56% in Black adults versus 48% in white adults. [1] That sustained pressure load translates into higher rates of hypertensive heart disease, left ventricular hypertrophy, heart failure with preserved ejection fraction, and hemorrhagic stroke.

Age-specific stroke incidence data from the CDC illustrate just how concentrated this burden is in mid-life: Black adults aged 45 to 54 experience stroke at approximately twice the rate of white adults in the same age band. [2] Years of life lost to CVD in Black communities run substantially higher than CDC headline mortality ratios suggest, because the deaths cluster in decades when white peers are still largely free of clinical disease.

Hispanic Adults: The Paradox and Its Limits

Hispanic adults present a more complex epidemiological picture. Aggregate CVD mortality in this group is lower than in non-Hispanic white adults despite higher prevalence of type 2 diabetes and obesity. Researchers call this the "Hispanic paradox" or "healthy immigrant effect," though the mechanisms remain debated. [3]

The paradox has real limits. Mexican-American adults carry some of the highest rates of diabetes-related cardiovascular complications in the country. Puerto Rican adults do not benefit from the same mortality advantage and show CVD death rates closer to those of non-Hispanic white peers. As Hispanic immigrant cohorts age and acculturate, their mortality advantage erodes. Clinicians should not allow a population-level paradox to reduce individual vigilance.

South Asian and Other Asian Subgroups

Aggregating all Asian Americans into one category is one of the more persistent errors in cardiovascular epidemiology. South Asian adults (from India, Pakistan, Bangladesh, Sri Lanka, and Nepal) face coronary artery disease risk two to four times higher than non-Hispanic white adults, with disease onset roughly a decade earlier. [4] The mechanism likely involves a combination of insulin resistance, atherogenic dyslipidemia (elevated small-dense LDL, high lipoprotein(a)), and truncal adiposity at body mass indexes that current screening thresholds classify as "normal."

East Asian adults generally record lower CVD mortality than white Americans, though Japanese-American and Korean-American adults show rising prevalence of metabolic syndrome with acculturation. The label "Asian" as a single risk category is clinically misleading.

Risk Factor Burden: What Drives the Disparity Gap?

Disparities in established CVD do not arise from biology alone. The differential risk-factor burden across racial and ethnic groups reflects decades of structural disadvantage, residential segregation, differential access to healthy food, occupational stress, and constrained access to preventive care.

Hypertension

Hypertension is the single biggest driver of excess CVD mortality in Black Americans. Black adults not only have higher prevalence but also experience more severe organ-level damage per unit of blood-pressure elevation. Salt sensitivity, lower renin activity, and sympathetic nervous system overactivation have all been proposed as mechanisms, though none tells the complete story.

The ALLHAT trial (N=33,357), which included a large Black cohort, found that chlorthalidone produced better cardiovascular outcomes than lisinopril in Black participants, a finding now reflected in ACC/AHA guideline recommendations favoring thiazide-type diuretics or calcium channel blockers as initial agents in Black adults without heart failure or chronic kidney disease. [5]

Type 2 Diabetes and Metabolic Syndrome

Diabetes roughly doubles cardiovascular risk across all racial groups, but the prevalence differential amplifies that effect. The CDC National Diabetes Statistics Report places diabetes prevalence at approximately 12.1% in Black adults, 11.8% in Hispanic adults, and 9.5% in white adults. [6] Among South Asian Americans, insulin resistance occurs at lower body weight thresholds, meaning standard BMI cutpoints underestimate metabolic risk in this group.

Lipids and Statin Initiation

The picture on lipids is more nuanced. Black Americans have, on average, higher HDL cholesterol than white peers, which the standard Pooled Cohort Equations (PCE) interpret as a risk-reducing factor. Research from the Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814) demonstrated, however, that coronary artery calcium (CAC) scoring reclassifies a meaningful proportion of Black adults from lower- to higher-risk categories that the PCE alone misses. [7]

Statin prescribing data consistently show that Black and Hispanic patients receive high-intensity statins less frequently than white patients after an acute MI, a gap that persists after adjusting for insurance status and comorbidities. [8]

Social Determinants and Structural Racism

Residential segregation concentrates environmental cardiovascular stressors: noise, air pollution, food deserts, and limited green space. A 2021 analysis in Circulation found that neighborhood-level socioeconomic disadvantage independently predicted 30-day heart failure readmission rates, and that the effect was roughly twice as large in Black patients as in white patients. [9] The AHA's 2021 Scientific Statement on structural racism and cardiovascular health formally named residential segregation, wealth gaps, and unequal criminal justice exposure as upstream determinants of the CVD disparity gap. [10]

Treatment Disparities: Where the Guideline Gap Lives

Even after accounting for differences in risk-factor burden and insurance status, Black and Hispanic patients with established CVD receive guideline-directed therapies at lower rates than white patients. This section traces the treatment gap across four major therapeutic categories.

Revascularization and Cardiac Procedures

NHLBI-supported registry data show that Black patients with obstructive coronary artery disease are approximately 40% less likely to undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) compared with white patients with similar angiographic disease burden. [11] A 2022 JAMA Cardiology analysis using Medicare data (N=approximately 1.2 million) replicated this finding and found the gap was not fully explained by patient preference, comorbidity burden, or hospital type. [12]

Heart Failure Therapy

Heart failure with reduced ejection fraction (HFrEF) offers one notable exception to the treatment-gap pattern, and it illustrates how trial design shapes inequity. The African American Heart Failure Trial (A-HeFT, N=1,050) demonstrated that isosorbide dinitrate plus hydralazine (BiDil) added to standard therapy reduced all-cause mortality by 43% in self-identified Black patients with HFrEF. [13] The FDA approved BiDil in 2005 specifically for Black patients. The existence of a race-specific approval remains scientifically controversial, since the trial enrolled only Black patients and could not determine whether the benefit was race-specific or reflected under-treatment with ACE inhibitors in the study cohort.

Beyond BiDil, SGLT2 inhibitors (dapagliflozin, empagliflozin) and sacubitril/valsartan now carry Class I recommendations for HFrEF regardless of race, yet post-approval claims analyses show that Black patients are initiated on these agents at rates 15 to 25% lower than white patients. [14]

Anticoagulation in Atrial Fibrillation

Black patients with atrial fibrillation have higher stroke rates than white patients at the same CHA₂DS₂-VASc score, yet they are less likely to receive any oral anticoagulation and, among those anticoagulated, less likely to achieve therapeutic INR with warfarin. Direct oral anticoagulants (DOACs) such as apixaban sidestep the INR management challenge, but prescribing data indicate Black and Hispanic patients with AF are still less likely to receive a DOAC compared with white patients after controlling for bleeding risk. [15]

Statin Therapy and LDL Targets

The ACC/AHA 2018 Cholesterol Guideline recommends high-intensity statin therapy for all patients with established ASCVD regardless of race or ethnicity. [16] Real-world adherence to this recommendation diverges sharply by race. A 2023 analysis of commercial and Medicaid claims found that Black adults with established ASCVD had high-intensity statin prescription rates approximately 22 percentage points lower than white adults in the same risk category, a gap that persisted even within the same health system and insurance type. [8]

The HealthRX Clinical Equity Framework for ASCVD management proposes a four-step approach for outpatient practices seeking to close these gaps:

1. Screen systematically. At every ASCVD encounter, document race/ethnicity, insurance status, social risk screen score (PRAPARE or AHC-HRSN), and current medication list with fill history.
2. Recalibrate risk. For patients of South Asian ancestry, apply a 1.5-to-2.0 risk multiplier to the PCE estimate and order CAC scoring when the result would change the treatment decision. For Black adults with PCE-estimated 10-year risk near a decision threshold, CAC scoring is similarly recommended by the 2019 AHA/ACC Primary Prevention Guideline.
3. Address adherence barriers before escalating dose. Pill burden, co-pay cards, 90-day supply mail pharmacy, and motivational interviewing are first-line before attributing non-adherence to patient behavior.
4. Close the referral loop. Track cardiology referral completion rates by race/ethnicity within your practice; a gap of more than 10 percentage points between groups warrants a quality-improvement review.

Stroke Disparities: A Closer Look

Stroke deserves separate attention because the racial gap is larger and the age-at-onset difference more pronounced than for coronary artery disease.

Incidence and Mortality by Race

The CDC WONDER database places age-adjusted stroke mortality in Black adults at approximately 1.5 times that of white adults overall, rising to roughly 2 times in the 45-to-64 age band. [2] The REGARDS study (Reasons for Geographic and Racial Differences in Stroke, N=30,239) found that the excess stroke incidence in Black adults was not fully explained by the higher prevalence of hypertension, diabetes, and atrial fibrillation. After adjusting for all measured risk factors, Black participants still showed a 35% higher stroke incidence than white participants. [17]

Secondary Prevention Gaps

After ischemic stroke, dual antiplatelet therapy, anticoagulation for cardioembolic etiology, blood pressure control below 130/80 mmHg, and high-intensity statin therapy are all Class I indicated. Black stroke survivors are less likely to be discharged on all four of these therapies simultaneously than white stroke survivors, and they are less likely to complete outpatient stroke neurology follow-up within 90 days. [18]

Guideline Positions on Race, Ethnicity, and CVD Risk

Multiple major societies have formally acknowledged that race and ethnicity modify cardiovascular risk in ways the standard Pooled Cohort Equations do not fully capture.

AHA/ACC 2019 Primary Prevention Guideline

The 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease lists "South Asian ancestry" and, conditionally, "Black race" among the risk-enhancing factors that clinicians should weigh when the decision to initiate statin therapy is uncertain after pooled cohort equation estimation. [19] The guideline states directly: "Among patients in whom statin initiation is uncertain based on the PCE, risk-enhancing factors favor statin therapy. South Asian ancestry is one such factor."

AHA 2020 Scientific Statement on Cardiovascular Disease in Black Adults

The AHA's 2020 Scientific Statement calls for standardized collection of race/ethnicity data in all cardiovascular registries, routine social determinants screening at CVD encounters, and payer-level accountability for procedure-rate disparities. The statement notes: "The persistent gap in cardiovascular outcomes between Black and white Americans reflects not individual biology but cumulative exposure to structural inequity that begins before birth." [10]

JNC and ISHIB Guidelines on Hypertension in Black Patients

The International Society on Hypertension in Blacks (ISHIB) recommends initiating antihypertensive therapy in Black adults at blood pressures of 135/85 mmHg or higher (lower than the 140/90 threshold historically used), given the earlier onset of target-organ damage documented in this group. [20]

Clinical Implications: What Practitioners Should Do Differently

The evidence across incidence, treatment, and outcomes data converges on a set of concrete actions that individual clinicians and health systems can implement.

Risk Assessment

Use coronary artery calcium scoring in Black and South Asian patients whose 10-year PCE risk falls in the 5 to 20% range where the treatment decision is uncertain. CAC of zero reclassifies patients to a lower-risk, statin-optional category; CAC above 100 Agatston units supports high-intensity statin initiation regardless of PCE output.

Antihypertensive Selection

For Black adults without heart failure, CKD with proteinuria, or diabetes-related nephropathy, initiate with a thiazide-type diuretic (chlorthalidone 12.5 to 25 mg daily) or a long-acting calcium channel blocker (amlodipine 5 to 10 mg daily) per the ALLHAT evidence base. ACE inhibitors as monotherapy show inferior blood pressure reduction in this population. [5]

Statin Adherence Programs

After ACS or established ASCVD, enroll Black and Hispanic patients in pharmacist-led adherence programs. A 2020 RCT published in JAMA Internal Medicine found that pharmacist-led telephonic medication management in a predominantly Black urban population reduced LDL by an additional 18 mg/dL compared with usual care over 12 months. [21]

SGLT2 Inhibitors and GLP-1 Receptor Agonists

For patients with established ASCVD and type 2 diabetes, the ADA 2024 Standards of Care recommend an SGLT2 inhibitor (empagliflozin or dapagliflozin) or a GLP-1 receptor agonist (semaglutide or liraglutide) with proven cardiovascular benefit regardless of HbA1c, prioritizing cardiorenal protection over glucose lowering alone. [22] Prescribing rates for both classes remain lower in Black and Hispanic patients with T2D and established CVD than in white peers, despite similar or greater expected absolute benefit given higher baseline event rates.

Research Gaps and What Comes Next

Several of the most consequential questions in cardiovascular equity research remain unanswered.

Trial representation is improving but still lagging. The DECLARE-TIMI 58 trial of dapagliflozin enrolled fewer than 5% Black participants despite the outsized prevalence of T2D-related CVD in this group. [23] The EMPEROR-Reduced trial of empagliflozin for HFrEF enrolled approximately 14% Black participants, closer to the US population share but still below the burden share. [24]

Lipoprotein(a) testing is underused across all populations but disproportionately underused in Black patients, despite data from the FOURIER trial showing that elevated Lp(a) predicts residual ASCVD risk independently of LDL in patients already on maximally tolerated statin therapy. [25]

Polygenic risk scores, built largely on European-ancestry genomic data, perform less accurately in African- and Hispanic-ancestry populations, meaning that genomic risk tools could widen rather than narrow the disparity gap if deployed without ancestry-appropriate calibration.